Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4361 - Genomic characterization of vulvar squamous cell carcinoma

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Translational Research

Tumour Site

Vulvar and Vaginal Cancers

Presenters

Katharina Prieske

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

K. Prieske1, M. Alawi2, S.A. Joosse3, K. Eylmann1, E. Burandt4, B. Schmalfeldt5, L. Oliveira-Ferrer1, L. Woelber1

Author affiliations

  • 1 Department Of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 2 Bioinformatics Core, University Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 3 Tumorbiology, University Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 4 Institute Of Pathology, University Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 5 Gynaecology, AGO Study Group & Technical University of Munich - Klinikum rechts der Isar; current address: University of Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
More

Resources

Abstract 4361

Background

Despite an increasing incidence, vulvar squamous cell cancer (VSCC) is still a rare disease. So far two etiological pathways have been described: A high-risk human papillomavirus (HPV)-dependent route and an HPV–independent pathway often associated with lichen sclerosus. To date, therapeutic strategies in VSCC are not influenced by molecularpathological information and therapeutic options for advanced or recurrent disease are limited.

Methods

Whole exome sequencing of DNA isolated from 34 VSCC samples and matched normal tissue for each individual was performed on an Illumina HiSeq4000. Short variant discovery was carried out using BWA and MuTect2. Variants were annotated using ANNOVAR. For the detection structural variants and copy number aberrations, Pindel, ADTEx and FREEC were employed. Presence of HPV integration sites was assessed using Bowtie2.

Results

All pts (median age 60) received surgery with (partial) vulvectomy as primary treatment. In 82% a surgical staging of the groins was performed. FIGO stages were: n = 5 IB, n = 13 II, n = 5 stage III and n = 2 IVA (n = 7 unknown). 10/34 (29.4%) samples were HPV positive (all HPV16). 17.6% pts suffered from recurrence (4 local, 2 groin, 1 pelvic) after a median of 10 months. TP53 mutations were most commonly detected, with 41% (14/34). Additionally, we observed mutations in the following genes, which were affected in at least three samples: MUC3A (7/34), FSIP2 (4/34), AKAP9 (4/34), TDRD15, PKD1L1, FCHO1, RANBP2, FBXW7, VPS13C, MDGA2, SCN9A, VEPH1, ABCA5, KIAA0368, NCAM2, GCC2, MYCBP2, PRPF39, WDR49, ZNF729, UTRN, ANKRD36, GRAMD1c, ADGRV1 in 3/34 samples. Significantly less mutations were detected in pts with a OS > 48 months (p = 0.032). However, there was no significant difference in PFS or OS between HPV positive and negative tumors (p = 0.78 and 0.92). In an univariate analysis there was a significant correlation between HPV negative tumors and TP53 mutations (p < 0.0001). No correlation between pT status, pN status, tumor size or number of mutations and HPV status was detected.

Conclusions

The key mutation in vulvar cancer affects TP53. This first work and progress analysis of whole exome sequencing of VSCC with corresponding normal tissue has the potential to identify further key mutations and therewith new targets for the treatment of VSCC.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Hamburger Krebsgesellschaft.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.